Pfizer Just Kept the ATTR-CM Market on Its Terms Until 2031

Pfizer just made the next phase of a rare heart disease drug war more expensive.

In a settlement announced Tuesday, Pfizer said generic versions of Vyndamax, its treatment for transthyretin amyloid cardiomyopathy, or ATTR-CM, now cannot enter the U.S. market until June 1, 2031, unless other litigation changes the outcome. ATTR-CM is a disease in which a misfolded protein stiffens the heart over time. The settlement sounds like patent housekeeping. It resets the competitive map for every company trying to sell a newer ATTR-CM drug into a market where the incumbent may stay branded, dominant, and expensive for years longer than expected.

That matters because Vyndamax is still the market's reference drug. Reuters reported that Pfizer sold nearly $6.4 billion of Vyndamax and related drugs in 2025. Pfizer said the drug still holds 75 percent of prescription volume in the overall ATTR-CM market and that it had previously expected a sharp U.S. revenue decline starting in 2029 before this settlement pushed that cliff out to mid-2031, according to the company's release. If you are BridgeBio, Alnylam, or the Ionis and AstraZeneca partnership, the problem is simple: tafamidis, the active ingredient sold as Vyndamax, stays the commercial reference point everyone else still has to beat.

A generic Vyndamax in 2029 would not automatically have won the market, but it could have lowered the price anchor for doctors, insurers, and patients deciding among ATTR-CM treatments. Now the field may spend two more years fighting on premium terrain instead.

BioPharma Dive reported that BridgeBio shares fell about 5 percent after the news. That reaction is not the story by itself, and type0 does not care about a one-day stock move for its own sake. It does tell you what investors thought they were buying: a market where Pfizer's incumbent franchise would face cheaper competition sooner. BridgeBio is already in that market with Attruby, its own ATTR-CM drug. A longer branded runway for Vyndamax means Attruby has to keep making the case against a still-entrenched branded rival, not against a category that has reset around a generic price.

The same logic reaches beyond BridgeBio. In March 2025, Alnylam said the FDA approved Amvuttra for adults with ATTR-CM to reduce cardiovascular death, cardiovascular hospitalizations, and urgent heart failure visits. Ionis said in February 2024 that its Phase 3 CARDIO-TTRansform study of eplontersen in ATTR-CM had enrolled more than 1,400 patients, according to the company's release. Those are different technologies chasing the same disease. Alnylam's RNA interference drug works by shutting down production of the harmful protein. Ionis is developing an antisense medicine, a drug that blocks the genetic instructions for making that protein, through a different mechanism. All of them still sell into a market where tafamidis has years of prescribing familiarity, outcomes data, and now more patent-protected time.

Pfizer leaned hard on that installed base in its announcement. The company said Vyndamax is backed by data from more than 7,000 patients and more than seven years of market leadership, in its release. Competitors would rather make that case against an aging drug that has already tipped into generic pricing. Instead, they may have to keep arguing not only that their drugs work, but that they are worth paying up for while the old standard remains premium.

There is still a reason not to overstate this. The settlement does not freeze the field. Alnylam already has an approved rival. BridgeBio is already selling one. Ionis and AstraZeneca are still pursuing a late-stage entrant. Doctors do not choose therapies on patent calendars alone, and outcomes data can overpower pricing in a life-threatening disease. The immediate effect here is less about patients suddenly losing access to a generic they were about to receive and more about the market staying on Pfizer's terms for longer.

That is why the story is more interesting than a patent squabble and less dramatic than a miracle save. Pfizer did not end competition in ATTR-CM. It delayed the moment when competitors could sell into a market with a cheaper incumbent baseline. For a disease area where each new entrant has promised some combination of better outcomes, easier dosing, or a stronger mechanism, that means the next few years may be spent proving superiority in the most expensive version of the game.